跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
C2 inhibitor
首页
药物
C2 inhibitor
C2 inhibitor
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
TREATMENT OR PREVENTION OF ISCHEMIA REPERFUSION INJURY IN ORGAN TRANPLANTATION
申请人: ARGENX BV
优先权: 2024
WO
COMBINATION ANTI-CANCER THERAPY
申请人: OSI PHARMACEUTICALS LLC
优先权: 2011
US
Methods of treating leukemia
申请人: SHIRE BIOCHEM INC
优先权: 2002
US
2 件公开
PD-L1 targeting small-molecule inhibitor, nano-particles prepared by combining PD-L1 targeting small-molecule inhibitor with photodynamic therapy, medicine and application of PD-L1 targeting small-molecule inhibitor and nano-particles
申请人: UNIV CAPITAL MEDICAL SCIENCES
优先权: 2025
CN
Corrosion inhibitor with improved performance at high temperatures
申请人: SCHLUMBERGER TECHNOLOGY CORP
优先权: 2019
US
2 件公开
Arylpiperazines having activity at the serotonin 1A receptor
申请人: GODFREY ALEXANDER GLENN
优先权: 2001
US
2 件公开
COMPOSITIONS AND METHODS FOR TREATING LUPUS NEPHRITIS
申请人: ANNEXON INC
优先权: 2022
CN
EP
US
WO
4 件公开
Application of 1, 2-bis(4-alkyl-7-hydroxycoumarin-8-ylmethenyl) hydrazine to tumor resistance
申请人: UNIV CHANGSHA SCIENCE & TECH
优先权: 2018
CN
药物
反馈